Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$26.12 - $34.07 $8.26 Million - $10.8 Million
-316,399 Reduced 12.54%
2,207,187 $75.2 Million
Q1 2024

May 15, 2024

BUY
$26.64 - $40.31 $8.02 Million - $12.1 Million
300,958 Added 13.54%
2,523,586 $88.8 Million
Q4 2023

Feb 14, 2024

BUY
$19.95 - $31.0 $2.83 Million - $4.4 Million
141,888 Added 6.82%
2,222,628 $64.2 Million
Q3 2023

Nov 14, 2023

SELL
$21.33 - $59.42 $2.38 Million - $6.63 Million
-111,645 Reduced 5.09%
2,080,740 $47.7 Million
Q2 2023

Aug 14, 2023

BUY
$34.33 - $62.11 $24.1 Million - $43.6 Million
702,624 Added 47.16%
2,192,385 $126 Million
Q1 2023

May 15, 2023

BUY
$26.01 - $48.69 $9.36 Million - $17.5 Million
359,764 Added 31.84%
1,489,761 $56.1 Million
Q4 2022

Feb 14, 2023

SELL
$24.14 - $30.37 $235,896 - $296,775
-9,772 Reduced 0.86%
1,129,997 $30.2 Million
Q3 2022

Nov 14, 2022

SELL
$22.23 - $33.37 $2.42 Million - $3.63 Million
-108,791 Reduced 8.71%
1,139,769 $32.3 Million
Q2 2022

Aug 15, 2022

BUY
$19.74 - $43.01 $2.68 Million - $5.85 Million
135,909 Added 12.21%
1,248,560 $27.1 Million
Q1 2022

May 16, 2022

SELL
$36.25 - $52.02 $1.22 Million - $1.75 Million
-33,710 Reduced 2.94%
1,112,651 $44.7 Million
Q4 2021

Feb 14, 2022

BUY
$43.27 - $65.72 $5.46 Million - $8.29 Million
126,142 Added 12.36%
1,146,361 $54.3 Million
Q3 2021

Nov 15, 2021

BUY
$53.61 - $67.5 $34.7 Million - $43.7 Million
646,868 Added 173.26%
1,020,219 $57.8 Million
Q2 2021

Aug 16, 2021

BUY
$45.13 - $64.99 $128,349 - $184,831
2,844 Added 0.77%
373,351 $21.4 Million
Q1 2021

May 17, 2021

BUY
$29.77 - $84.85 $11 Million - $31.4 Million
370,507 New
370,507 $23.4 Million

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.